Home World News Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate... World News Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less By Ogkologos - March 5, 2026 382 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POSEIDON meta-analysis of the MARCAP consortium Source RELATED ARTICLESMORE FROM AUTHOR How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research MOST POPULAR Spending Review 2021: Promising commitments, but a lot of unanswered questions October 27, 2021 Exercising While Living With Peripheral Neuropathy: What People Diagnosed With Cancer... May 2, 2023 9-Year-Old Has His Final Cancer Treatment After 3 Years – Breaks... January 27, 2020 High Risk of BCSM at 20 Years in Men with Hormone... March 1, 2024 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Generic Sunitinib Celebrate with Us! Vaccine Rollouts Mark the Light at the End... Addressing Common Sexual Health Concerns During Cancer Survivorship: An Expert Perspective New study to detect oesophageal cancer earlier